Foresee Pharmaceuticals Receives Positive CHMP Opinion to Approved CAMCEVI 21mg for Advanced Prostate Cancer in the EU

Foresee Pharmaceuticals Welcomes Major Regulatory Milestone for CAMCEVI

Foresee Pharmaceuticals, a notable player in the biopharmaceutical industry, recently announced a significant breakthrough concerning its cancer treatment product, CAMCEVI. On March 6, 2026, the company revealed that its licensing partner, Accord Healthcare, had informed them of a favorable opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). This positive recommendation is set to extend the marketing authorization for CAMCEVI to include the 21mg, 3-month ready-to-use strength formulation specifically designed for advanced prostate cancer.

Enhancing Patient Care with Innovative Solutions

The issuance of a favorable CHMP opinion marks an essential regulatory milestone, providing renewed hope for patients battling advanced prostate cancer and the healthcare providers dedicated to their treatment. CAMCEVI 21mg is an innovative subcutaneous leuprolide injection that eliminates the traditional complexities associated with treatment preparation. Unlike conventional therapies that often require intricate multi-step mixing methods, the new formulation offers a straightforward administration process. This advancement not only simplifies the clinical operation but also enhances patient comfort as well as adherence to the treatment regimen.

One of the standout features of CAMCEVI 21mg is its convenience; it comes with a three-month dosing interval. This offers an attractive option in conjunction with the previously available CAMCEVI 42mg, which has already been beneficial in reducing treatment burden. The 21mg version will further streamline the administration process for clinical staff, contributing to increased operational efficiency whilst ensuring patients receive timely and consistent care.

Next Steps in the Approval Process

Following this positive opinion by CHMP, the final authority on medicinal approvals in the EU, the European Commission (EC) will conduct its review. A final decision regarding marketing authorization is anticipated in the second quarter of 2026, a development that industry insiders are watching closely due to its potential to impact cancer care practices across Europe significantly.

Under a strategic partnership framework, Accord Healthcare has exclusive rights to commercialize CAMCEVI throughout the European market. The anticipated approval of the 21mg, three-month strength will build upon the successful launch of the CAMCEVI 42mg, which debuted in Europe in 2025.

About Foresee Pharmaceuticals

Foresee Pharmaceuticals is a biopharmaceutical company of Taiwanese and US origin listed on the Taipei Exchange (TPEx 6576). The company’s research and development activities target two critical areas: unique long-acting injectable (LAI) technology and groundbreaking new chemical entities aimed at treating rare and severe disease conditions with key unmet needs.

The portfolio includes several innovative products at varying developmental stages. CAMCEVI 42mg for advanced prostate cancer has already gained approval in multiple jurisdictions, such as the U.S., Canada, EU, Taiwan, Israel, and the UK, with its U.S. launch having occurred in April 2022. Additionally, Foresee has made impressive strides in its other product lines. For instance, CAMCEVI ETM received FDA approval on August 25, 2025, and efforts surrounding its 3-month formulation continue with an ongoing EU regulatory review.

Furthermore, Foresee’s pipeline includes ongoing projects such as the CAMCEVI 6-month LAI formulation, which is currently undergoing clinical trials with a robust focus. Their innovative work also extends to therapies intended for addressing conditions such as central precocious puberty and various inflammatory diseases. The biopharmaceutical arena is evolving, and with companies like Foresee leading the charge; there is great optimism for the future of medical treatments in specialty markets.

For more information on Foresee Pharmaceuticals and its portfolio, visit Foresee Pharmaceuticals.